GH Research PLC (NASDAQ:GHRS) Given Average Recommendation of “Moderate Buy” by Analysts

GH Research PLC (NASDAQ:GHRS) has received an average rating of “Moderate Buy” from the twelve ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and ten have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $45.00.

Several brokerages recently commented on GHRS. Zacks Research upgraded shares of GH Research from a “strong sell” rating to a “hold” rating in a research note on Thursday, August 13th. Needham & Company LLC upped their target price on shares of GH Research from $32.00 to $39.00 and gave the stock a “buy” rating in a research report on Thursday, August 6th. Wall Street Zen raised shares of GH Research from a “sell” rating to a “hold” rating in a report on Saturday, August 8th. Weiss Ratings reiterated a “sell (d-)” rating on shares of GH Research in a research report on Friday, July 17th. Finally, New Street Research set a $65.00 price target on GH Research in a research note on Monday, August 10th.

GH Research Stock Performance

Shares of GHRS stock opened at $28.23 on Tuesday. The company has a market capitalization of $1.94 billion, a P/E ratio of -28.23 and a beta of 1.27. The business’s 50 day moving average is $28.14 and its two-hundred day moving average is $22.11. GH Research has a twelve month low of $11.83 and a twelve month high of $31.44.

GH Research (NASDAQ:GHRS) last released its earnings results on Thursday, August 6th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.29) by $0.06. As a group, equities analysts predict that GH Research will post -1.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On GH Research

Large investors have recently bought and sold shares of the stock. JPMorgan Chase & Co. acquired a new stake in GH Research during the second quarter worth approximately $79,000. BNP Paribas Financial Markets raised its holdings in GH Research by 165.4% in the 2nd quarter. BNP Paribas Financial Markets now owns 17,010 shares of the company’s stock valued at $207,000 after acquiring an additional 10,600 shares during the last quarter. Osaic Holdings Inc. lifted its stake in shares of GH Research by 63.6% during the 2nd quarter. Osaic Holdings Inc. now owns 6,175 shares of the company’s stock worth $75,000 after purchasing an additional 2,400 shares during the period. UBS Group AG lifted its stake in shares of GH Research by 11.5% during the 3rd quarter. UBS Group AG now owns 511,464 shares of the company’s stock worth $7,314,000 after purchasing an additional 52,882 shares during the period. Finally, Lynx1 Capital Management LP boosted its holdings in shares of GH Research by 27.5% during the third quarter. Lynx1 Capital Management LP now owns 8,601,189 shares of the company’s stock worth $122,997,000 after purchasing an additional 1,854,238 shares during the last quarter. Institutional investors and hedge funds own 56.90% of the company’s stock.

GH Research Company Profile

GH Research Holdings Inc is a clinical-stage biotechnology company dedicated to the development of novel treatments for neuropsychiatric disorders through the application of psychedelic-inspired compounds. Headquartered in Dublin, Ireland, the company focuses on harnessing the unique pharmacology of 5-methoxy-N-dimethyltryptamine (5-MeO-DMT) and related molecules to address high unmet medical needs in mental health.

The firm’s lead program, GH001, is an inhaled formulation of 5-MeO-DMT that has completed early-stage clinical trials assessing safety, tolerability and preliminary efficacy in treatment-resistant depression.